[New approaches to the therapy of rheumatoid arthritis].
Design of highly selective biological substances made use of three basic components of a complex pathogenetic model of RA: the presence of antigen-presenting cells, genetic defects and autoimmune aggression. Efforts now are directed to development of monoclonal antibodies (MAB) to receptors of T-cells, B lymphocytes, MAB to CD 18 and CD54, cytokines, search for natural inhibitors of cytokines, introduction of cytokines. Many of such preparations including recombinant interferons proved clinically promising.
Balabanova
R M
RM
Egorova
O N
ON
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000276:immunology / Q000628:therapy*; D016207:Cytokines / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D016207:Cytokines
Novye podkhody k terapii revmatoidnogo artrita.